ArticleBiomedicines2021
Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Single Low-Carbohydrate, High-Fat Meal Consumption on Postprandial Lipemia and Markers of Endothelial Dysfunction: A Systematic Review of Current Evidence.Nutrition reviews · 2025Pooled it
- Disease-specific crosstalk of Alistipes with lipoprotein profiles in overweight individuals at high cardiometabolic risk.Scientific reports · 2026Article
- Exercise-induced hypertension, atherogenic lipid subfractions, and cardiorespiratory fitness in marathon runners.Preventive medicine reports · 2026Article
- Article
- Superior prognostic value of estimated small dense LDL cholesterol for cardiovascular risk assessment: evidence from international cohort studies.Lipids in health and disease · 2025Article
- The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review.Journal of cardiovascular development and disease · 2025Review
- Relationship of small dense low-density lipoprotein cholesterol level with pre-diabetes and newly detected type 2 diabetes.Scientific reports · 2025Article
- Atherogenic lipid parameters in people with normal glucose tolerance: implications from elevated 1-hour post-load plasma glucose.Cardiovascular diabetology · 2025Article
- Statin utilization and its predictors for the primary prevention of cardiovascular disease among type 2 diabetic patients in a resource-limited setting.Frontiers in endocrinology · 2025Article
- Article
- An equation for calculating small dense low-density lipoprotein cholesterol.Lipids in health and disease · 2024Article
- Chemerin in the Spotlight: Revealing Its Multifaceted Role in Acute Myocardial Infarction.Biomedicines · 2024Review
- Relationship between LDL-cholesterol, small and dense LDL particles, and mRNA expression in a cohort of African Americans.American journal of physiology. Heart and circulatory physiology · 2024Article
- Determining the status of small dense low-density lipoprotein cholesterol level in women undergoing menopausal transition.Frontiers in endocrinology · 2024Article
- Fish consumption and its lipid modifying effects - A review of intervention studies.Neurotoxicology · 2023Review
- Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk.Biomedicines · 2023Review
- Lipoprotein Particle Profiles Associated with Telomere Length and Telomerase Complex Components.Nutrients · 2023Article
- Cholesterol efflux capacity is increased in subjects with familial hypercholesterolemia in a retrospective case-control study.Scientific reports · 2023Article
- Remnant cholesterol can identify individuals at higher risk of metabolic syndrome in the general population.Scientific reports · 2023Article
- Exploring the Association between Low-Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomes-A Comprehensive Review.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atherosclerosis and cardiovascular events. In addition to the traditionally available lipid-lowering treatment options, certain novel therapies have been shown to favorably impact sdLDL, among them the antidiabetic class of agents known as glucagon-like peptide 1 receptor agonists (GLP1-RAs). These drugs seem to alter the pathophysiologic mechanisms responsible for the formation and accumulation of atherogenic lipoprotein particles, thus potentially reducing cardiovascular outcomes. They represent a uniquely targeted therapeutic approach to reduce cardiometabolic risk and warrant further study for their beneficial nonglycemic actions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.